Evogene Operating Income from 2010 to 2026
| EVGN Stock | USD 0.82 0.07 7.87% |
Operating Income | First Reported 2011-12-31 | Previous Quarter -3.1 M | Current Value -2.7 M | Quarterly Volatility 2.1 M |
Check Evogene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evogene's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.5 M, Interest Expense of 201.5 K or Selling General Administrative of 6 M, as well as many indicators such as Price To Sales Ratio of 1.16, Dividend Yield of 0.0 or Days Sales Outstanding of 54.52. Evogene financial statements analysis is a perfect complement when working with Evogene Valuation or Volatility modules.
Evogene | Operating Income | Build AI portfolio with Evogene Stock |
Evaluating Evogene's Operating Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Evogene's fundamental strength.
Latest Evogene's Operating Income Growth Pattern
Below is the plot of the Operating Income of Evogene over the last few years. Operating Income is the amount of profit realized from Evogene operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Evogene is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Evogene's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Evogene's overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Evogene Operating Income Regression Statistics
| Arithmetic Mean | (18,502,778) | |
| Coefficient Of Variation | (48.65) | |
| Mean Deviation | 7,011,961 | |
| Median | (21,089,000) | |
| Standard Deviation | 9,001,223 | |
| Sample Variance | 81T | |
| Range | 28.3M | |
| R-Value | (0.78) | |
| Mean Square Error | 34.4T | |
| R-Squared | 0.60 | |
| Significance | 0.0003 | |
| Slope | (1,383,182) | |
| Total Sum of Squares | 1296.4T |
Evogene Operating Income History
About Evogene Financial Statements
Evogene investors utilize fundamental indicators, such as Operating Income, to predict how Evogene Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | -19.6 M | -20.5 M |
Pair Trading with Evogene
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evogene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evogene will appreciate offsetting losses from the drop in the long position's value.Moving against Evogene Stock
| 0.57 | DSGN | Design Therapeutics | PairCorr |
| 0.54 | EQ | Equillium | PairCorr |
| 0.5 | DRTS | Alpha Tau Medical | PairCorr |
| 0.49 | 6C1 | CytomX Therapeutics | PairCorr |
| 0.49 | SAB | Sonic Healthcare | PairCorr |
The ability to find closely correlated positions to Evogene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evogene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evogene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evogene to buy it.
The correlation of Evogene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evogene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evogene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evogene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Evogene Correlation against competitors. To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Will Biotechnology sector continue expanding? Could Evogene diversify its offerings? Factors like these will boost the valuation of Evogene. Projected growth potential of Evogene fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Evogene data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.10) | Revenue Per Share | Quarterly Revenue Growth (0.83) | Return On Assets | Return On Equity |
Investors evaluate Evogene using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Evogene's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Evogene's market price to deviate significantly from intrinsic value.
It's important to distinguish between Evogene's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Evogene should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Evogene's market price signifies the transaction level at which participants voluntarily complete trades.